Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

AUA2021: Gemtesa effective in overactive bladder wet and dry

By Brian Buntz | September 20, 2021

UrovantUrovant’s Gemtesa (vibegron) was the subject of two positive presentations at the Annual Meeting of the American Urological Association (AUA2021).  

The first explained that vibegron is effective in patients with ‘dry’ overactive bladder (OAB) based on a post-hoc analysis of the pivotal EMPOWUR trial. The second presentation explained that vibegron had a negligible impact on ambulatory blood pressure in a randomized, double-blind, placebo-controlled study. 

Vibegron, a beta-3 agonist, stands out in a market of overactive bladder drugs that are primarily antimuscarinics. “There’s only one other beta-3 agonist on the market,” said Dr. David Staskin, who was the international lead investigator in the EMPOWUR trial. 

The drug is also unique in that its label includes data on urgency associated with OAB. “It’s the first time [urgency] has ever been in a package insert for any overactive bladder drug,” said Staskin, who is also an associate professor of urology at Tufts University School of Medicine. 

“The syndrome is urgency, frequency, with or without incontinence,” Staskin explained. For that reason, ‘urgency’ is commonly mentioned on the labels of OAB drugs. But vibegron is the first to win FDA’s backing to have graphics and data associated with urgency on the label. “The Phase 3 study [for vibegron] was very robust,” Staskin said. “The patients used an electronic diary to answer urge questions that were very specific.” 

One of the two AUA2021 vibegron presentations focused on patients with ‘dry’ OAB based on a post-hoc analysis of data from the pivotal EMPOWUR study. Roughly one-quarter of participants in the EMPOWUR study had so-called OAB dry, which involves frequency and urgency but not incontinence. “So, the question for doctors is, ‘I have someone who came into my office the other day, and he or she has frequency and urgency and is getting up at night, but they don’t have accidents. Will the drug work for the OAB dry population as well as the OAB wet population?’” Staskin asked. “And this analysis showed that the answer was ‘yes, the drug works equally and OAB wet and OAB dry.’”

In the pivotal EMPOWUR study, vibegron led to a 60% reduction in urge incontinence episodes, which points to its efficacy, Staskin said. “If a drug is to exceed 1.5 times the placebo response within the first three months, it is considered very good,” he said. “That’s where the drug ended up actually almost mathematically at 1.5 times.”

After winning FDA approval in late 2020, vibegron hit the U.S. market in April. 


Filed Under: Urology
Tagged With: American Urological Association, AUA2021, EMPOWUR, Gemtesa, OAB, overactive bladder, Urovant
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
Futura Medical
Why Futura Medical believes MED3000 could disrupt the market for PDE5i drugs like Viagra and Cialis 
Urovant
A closer look at Urovant’s vibegron blood pressure study
Urovant
Urovant shares positive data at the annual meeting of the American Urological Association
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE